| 词条 | Mofegiline |
| 释义 |
| IUPAC_name = (2E)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine | image = Mofegiline.svg | CAS_number = 119386-96-8 | ATC_prefix = None | ATC_suffix = | UNII = 1FMJ6D8Y1B | PubChem = 6437850 | ChemSpiderID = 4942371 | C = 11 | H = 13 | F = 2 | N = 1 | molecular_weight = 197.224 g/mol | smiles = Fc1ccc(cc1)CCC(=[C@H]F)CN | synonyms = MDL-72,974A | StdInChI = 1S/C11H13F2N/c12-7-10(8-14)2-1-9-3-5-11(13)6-4-9/h3-7H,1-2,8,14H2/b10-7+ | StdInChIKey = VXLBSYHAEKDUSU-JXMROGBWSA-N | bioavailability = | protein_bound = | metabolism = | elimination_half-life = 1–3 hours[1] | excretion = Urine[2] | pregnancy_category = | legal_status = Development terminated | routes_of_administration = Oral[1] }}Mofegiline (MDL-72,974) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) and semicarbazide-sensitive amine oxidase (SSAO) which was under investigation for the treatment of Parkinson's disease and Alzheimer's disease,[3][4][5][6] but was never marketed.[7] See also
References1. ^1 {{cite journal | vauthors = Stoltz M, Reynolds D, Elkins L, Salazar D, Weir S | title = Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial | journal = Clinical Pharmacology and Therapeutics | volume = 58 | issue = 3 | pages = 342–53 |date=September 1995 | pmid = 7554709 | doi = 10.1016/0009-9236(95)90252-X }} {{Antioxidants}}{{Antidementia}}{{Antiparkinson}}{{Monoamine metabolism modulators}}2. ^{{cite journal |vauthors=Dulery BD, Schoun J, Zreika M, etal | title = Pharmacokinetics of and monoamine oxidase B inhibition by (E)-4-fluoro-beta-fluoromethylene benzene butanamine in man | journal = Arzneimittel-Forschung | volume = 43 | issue = 3 | pages = 297–302 |date=March 1993 | pmid = 8489556 | doi = | url = }} 3. ^{{cite journal | vauthors = Palfreyman MG, McDonald IA, Bey P, Schechter PJ, Sjoerdsma A | title = Design and early clinical evaluation of selective inhibitors of monoamine oxidase | journal = Progress in Neuro-psychopharmacology & Biological Psychiatry | volume = 12 | issue = 6 | pages = 967–87 | year = 1988 | pmid = 3266532 | doi = 10.1016/0278-5846(88)90092-9| url = }} 4. ^{{cite journal | vauthors = Zreika M, Fozard JR, Dudley MW, Bey P, McDonald IA, Palfreyman MG | title = MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease | journal = Journal of Neural Transmission. Parkinson's Disease and Dementia Section | volume = 1 | issue = 4 | pages = 243–54 | year = 1989 | pmid = 2597310 | doi = 10.1007/bf02263478| url = }} 5. ^{{cite journal | vauthors = Palfreyman MG, McDonald IA, Bey P, Danzin C, Zreika M, Cremer G | title = Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential | journal = Journal of Neural Transmission. Supplementum | volume = 41 | issue = | pages = 407–14 | year = 1994 | pmid = 7931257 | doi = 10.1007/978-3-7091-9324-2_54| url = | isbn = 978-3-211-82521-1 }} 6. ^{{cite journal | vauthors = Thiffault C, Quirion R, Poirier J | title = Effect of the MAO-B inhibitor, MDL72974, on superoxide dismutase activity and lipid peroxidation levels in the mouse brain | journal = Synapse | volume = 28 | issue = 3 | pages = 208–11 |date=March 1998 | pmid = 9488505 | doi = 10.1002/(SICI)1098-2396(199803)28:3<208::AID-SYN3>3.0.CO;2-E | url = }} 7. ^{{ cite book | author1 = Ganellin, C. R. | author2 = Triggle, D. J. | author3 = Macdonald, F. | title = Dictionary of pharmacological agents | url = https://books.google.com/books?id=A0THacd46ZsC&pg=PA1370 | accessdate = 25 November 2011 | year = 1997 | publisher = CRC Press | isbn = 978-0-412-46630-4 | page = 1370 }} 4 : Abandoned drugs|Antidementia agents|Antiparkinsonian agents|Monoamine oxidase inhibitors |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。